# QTX3046 in Patients With KRAS G12D Mutations

> **NCT06428500** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Quanta Therapeutics** · enrollment: 240 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** QTX3046
- **COMBINATION_PRODUCT:** Cetuximab

## Key facts

- **NCT ID:** NCT06428500
- **Lead sponsor:** Quanta Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-05-30
- **Primary completion:** 2027-07-01
- **Final completion:** 2027-07-01
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2025-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06428500

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06428500, "QTX3046 in Patients With KRAS G12D Mutations". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06428500. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*